1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Naurex Spinout Aptinyx Launches After Allergan Deal

 
• By Mandy Jackson

Work did not slow down at Naurex after its acquisition by Allergan for $560m up front – a return of at least 3.4 times the $163m in venture capital invested in the company – since the underlying technology platform was spun out in a new firm, which launched on Sept. 16 as Aptinyx.

Work did not slow down at Naurex after its acquisition by Allergan for $560m up front – a return of at least 3.4 times the $163m in venture capital invested in the company – since the underlying technology platform was spun out in a new firm, which launched on Sept. 16 as Aptinyx.

Aptinyx retained the entire Naurex management team and staff, including president and CEO Norbert Riedel, who told Scrip that Naurex's...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Supernus Secures Sage With CVR-Supported Deal

 
• By Jessica Merrill

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 
• By Andrew McConaghie

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.

More from Therapy Areas

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.